![CNBG Vaccine](https://custom-images.strikinglycdn.com/res/hrscywv4p/image/upload/c_limit,fl_lossy,h_1000,w_500,f_auto,q_auto/6127830/632294_641444.png)
CNBG Vaccine
centres in six states of Brazil, and plans to recruit nearly 9000 volunteers, who will start joining the
group this month after receiving ethical approval from each research center. This clinical study
will further validate the safety and effectiveness of the new inactivated crown vaccine KerrifoTM in Brazil,
which is a key study to support the licensing of the vaccine.
Heavy!
National Pharmaceutical Group China Biological COVID-19 Vaccine large-scale Emergency use Safety data. On April 21,
the Chinese Journal of Epidemiology published a paper entitled "Safety Evaluation of large-scale Emergency use of novel coronavirus inactivated
Vaccine (Vero cells)", which was released based on the large-scale emergency use safety evaluation of novel coronavirus inactivated vaccine of China
Biological Beijing products Research Institute and Wuhan Biological products Research Institute of Sinopharmaceutical Group.
Studies have shown that after emergency use of large-scale inactivatedcoronavirus vaccine (Vero cells), the incidence of general reaction is low,
there is no serious adverse reaction, and the vaccine county has good safety.
China Biology Beijing Institute: "generally, pain, tenderness, redness, swelling and itching may occur in injectionministries within 24 hours after vaccination,
and in most cases disappear within 2-3 days."The head of China Biology of the National Pharmaceutical Group disclosed in an interview with the media
on the emergency use of the new crown inactivated vaccine and the clinical research on the construction periodof overseas workers I,
that the emergency use of the two new crown inactivated vaccines developed by Chinesemedicine China has been vaccinated hundreds of thousands of times,
without any obvious adverse reactions andno infection; among them, tens of thousands of people who went to overseas high-risk countries and regions
after vaccination have achieved zero infection so far. Kexing Holdings Biotechnology Co., Ltd.: the current clinical data show that the observed adverse reactions
are mainly local pain at the injection site, followed by fatigue and local swelling, all of which are transient. Only a very small numberof fever and allergic reactions were observed,
and no serious adverse reactions were observed, indicating that the safety of the vaccine was good. About 3000 employees and family members of Kexing
Company were injected with COVID-19 vaccine.
https://www.who.int/news/item/07-05-2021-who-lists-additional-covid-19-vaccine-for-emergency-use-and-issues-interim-policy-recommendations